Literature DB >> 29100870

Rationing potentially inappropriate treatment in newborn intensive care in developed countries.

Dominic Wilkinson1, Stavros Petrou2, Julian Savulescu3.   

Abstract

In newborn intensive care, parents sometimes request treatment that professionals regard as 'futile' or 'potentially inappropriate'. One reason not to provide potentially inappropriate treatment is because it would be excessively costly relative to its benefit. Some public health systems around the world assess the cost-effectiveness of treatments and selectively fund those treatments that fall within a set threshold. This article explores the application of such thresholds to questions in newborn intensive care: (i) when a newborn infant's chance of survival is too small; (ii) how long treatment should continue; (iii) when quality of life is too low; and (iv) when newborn infants are too premature for cost-effective intensive care. This analysis yields some potentially surprising conclusions. Newborn intensive care may be cost-effective even in the setting of very low probability of survival, very poor predicted quality of life, for protracted periods of time, or for the most premature of newborns.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-benefit analysis; Intensive care; Medical ethics; Medical futility; Withholding treatment

Mesh:

Year:  2017        PMID: 29100870     DOI: 10.1016/j.siny.2017.10.004

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  2 in total

1.  The limits of viability of extremely preterm infants.

Authors:  Michael H Malloy; Leonard K Wang
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-05

Review 2.  An Immature Science: Intensive Care for Infants Born at ≤23 Weeks of Gestation.

Authors:  Matthew A Rysavy; Katrin Mehler; André Oberthür; Johan Ågren; Satoshi Kusuda; Patrick J McNamara; Regan E Giesinger; Angela Kribs; Erik Normann; Susan J Carlson; Jonathan M Klein; Carl H Backes; Edward F Bell
Journal:  J Pediatr       Date:  2021-03-07       Impact factor: 6.314

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.